158 related articles for article (PubMed ID: 38572480)
1. A study on the correlations of PRL levels with anxiety, depression, sleep, and self-efficacy in patients with prolactinoma.
Miao X; Fu Z; Luo X; Wang J; Yuan L; Zhao S; Feng Y; Huang S; Xiao S
Front Endocrinol (Lausanne); 2024; 15():1369729. PubMed ID: 38572480
[TBL] [Abstract][Full Text] [Related]
2. MANAGEMENT AND OUTCOMES OF GIANT PROLACTINOMA: A SERIES OF 71 PATIENTS.
Hamidi O; Van Gompel J; Gruber L; Kittah NE; Donegan D; Philbrick KA; Koeller KK; Erickson D; Natt N; Nippoldt TB; Young WF; Bancos I
Endocr Pract; 2019 Apr; 25(4):340-352. PubMed ID: 30995432
[No Abstract] [Full Text] [Related]
3. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
[No Abstract] [Full Text] [Related]
4. Enhanced slow wave sleep in patients with prolactinoma.
Frieboes RM; Murck H; Stalla GK; Antonijevic IA; Steiger A
J Clin Endocrinol Metab; 1998 Aug; 83(8):2706-10. PubMed ID: 9709935
[TBL] [Abstract][Full Text] [Related]
5. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
6. Low recurrence rate after partial hypophysectomy for prolactinoma: the predictive value of dynamic prolactin function tests.
Webster J; Page MD; Bevan JS; Richards SH; Douglas-Jones AG; Scanlon MF
Clin Endocrinol (Oxf); 1992 Jan; 36(1):35-44. PubMed ID: 1559298
[TBL] [Abstract][Full Text] [Related]
7. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction.
Corona G; Mannucci E; Jannini EA; Lotti F; Ricca V; Monami M; Boddi V; Bandini E; Balercia G; Forti G; Maggi M
J Sex Med; 2009 May; 6(5):1457-66. PubMed ID: 19210705
[TBL] [Abstract][Full Text] [Related]
8. Giant prolactinomas larger than 60 mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas.
Shimon I; Sosa E; Mendoza V; Greenman Y; Tirosh A; Espinosa E; Popovic V; Glezer A; Bronstein MD; Mercado M
Pituitary; 2016 Aug; 19(4):429-36. PubMed ID: 27138902
[TBL] [Abstract][Full Text] [Related]
9. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
10. Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
Williams TA; Dietz AS; Theodoropoulou M; Riester A; Fischer E; Burrello J; Treitl M; Geyer L; Veglio F; Bidlingmaier M; Schopohl J; Beuschlein F; Mulatero P; Reincke M
J Clin Endocrinol Metab; 2015 Sep; 100(9):E1262-9. PubMed ID: 26176803
[TBL] [Abstract][Full Text] [Related]
11. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance imaging measurements of pituitary stalk compression and deviation in patients with nonprolactin-secreting intrasellar and parasellar tumors: lack of correlation with serum prolactin levels.
Smith MV; Laws ER
Neurosurgery; 1994 May; 34(5):834-9; discussion 839. PubMed ID: 8052379
[TBL] [Abstract][Full Text] [Related]
13. Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth?
Alkabbani AG; Mon SY; Hatipoglu B; Kennedy L; Faiman C; Weil RJ; Hamrahian AH
Pituitary; 2014 Apr; 17(2):97-102. PubMed ID: 23468127
[TBL] [Abstract][Full Text] [Related]
14. Falsely low serum prolactin in two cases of invasive macroprolactinoma.
Schöfl C; Schöfl-Siegert B; Karstens JH; Bremer M; Lenarz T; Cuarezma JS; Samii M; von zur Mühlen A; Brabant G
Pituitary; 2002; 5(4):261-5. PubMed ID: 14558675
[TBL] [Abstract][Full Text] [Related]
15. PRL-R Variants Are Not Only Associated With Prolactinomas But Also With Dopamine Agonist Resistance.
de Castro Moreira AR; Trarbach E; Bueno CBF; Monteiro ALS; Grande IPP; Padula M; Maciel GAR; Glezer A
J Clin Endocrinol Metab; 2023 Jun; 108(7):e450-e457. PubMed ID: 36638053
[TBL] [Abstract][Full Text] [Related]
16. [Inhibitory effects of melatonin on the development of 17-beta-estradiol induced prolactinoma in relation to plasma prolactin and peroxidative lipid contents].
Gao L; Xu JP; Shan HM; Zhang R; Xu RK
Sheng Li Xue Bao; 2001 Jun; 53(3):165-9. PubMed ID: 12589398
[TBL] [Abstract][Full Text] [Related]
17. Primary medical therapy of micro- and macroprolactinomas in men.
Pinzone JJ; Katznelson L; Danila DC; Pauler DK; Miller CS; Klibanski A
J Clin Endocrinol Metab; 2000 Sep; 85(9):3053-7. PubMed ID: 10999785
[TBL] [Abstract][Full Text] [Related]
18. SHORT-TERM DECLINE IN PROLACTIN CONCENTRATIONS CAN PREDICT FUTURE PROLACTIN NORMALIZATION, TUMOR SHRINKAGE, AND TIME TO REMISSION IN MEN WITH MACROPROLACTINOMAS.
Tirosh A; Benbassat C; Shimon I
Endocr Pract; 2015 Nov; 21(11):1240-7. PubMed ID: 26247115
[TBL] [Abstract][Full Text] [Related]
19. Incidence and characteristics of microprolactinomas (3-5 mm) in 4199 women assayed for prolactin.
Batrinos ML; Panitsa-Faflia C; Tsiganou E; Liapi C
Horm Metab Res; 1992 Aug; 24(8):384-91. PubMed ID: 1526627
[TBL] [Abstract][Full Text] [Related]
20. [Melatonin inhibits the proliferation of pituitary prolactin-secreting tumor by suppressing the enhancer elements mutation of PRL gene in the rat].
Gao L; Yang QH; Xu RK
Sheng Li Xue Bao; 2005 Jun; 57(3):319-27. PubMed ID: 15968426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
